The National Institutes of Health announced Monday it was enrolling hundreds of people in phase 2 clinical trials that will evaluate at least four potential treatments for long COVID.
The news underscores that the government recognizes the importance of developing treatment therapies to improve the lives of thousands of people who never completely recovered from the novel coronavirus, Northeastern researchers Kristin Kostka and Mauricio Santillana say.
“There is now a shift of acknowledging it’s not in people’s heads. And that’s progress,” says Kostka, director of the Observational Health Data Sciences and Informatics (OHDSI) at Northeastern’s Roux Institute.
Santillana, who directs Northeastern’s Machine Intelligence Group for the betterment of Health and the Environment (MIGHTE) in the Network Science Institute, says it’s a step in the…
